icp-022
Showing 1 - 8 of 8
Systemic Lupus Erythematosus Trial in China (ICP-022, Placebos)
Completed
- Systemic Lupus Erythematosus
- ICP-022
- Placebos
-
Bengbu, Anhui, China
- +10 more
Nov 28, 2022
CLL/SLL Trial in China (ICP-022)
Active, not recruiting
- CLL/SLL
- ICP-022
-
Hefei, Anhui, China
- +24 more
Jul 5, 2022
Mantle Cell Lymphoma Trial in China (ICP-022)
Active, not recruiting
- Mantle Cell Lymphoma
- ICP-022
-
Hefei, Anhui, China
- +30 more
Jul 5, 2022
PCNSL, Secondary CNS Lymphoma Trial in Beijing, Guangzhou, Shanghai (ICP-022)
Recruiting
- PCNSL
- Secondary Central Nervous System Lymphoma
- ICP-022
-
Beijing, Beijing, China
- +4 more
Jul 28, 2021
Diffuse Large B Cell Lymphoma Trial in China (ICP-022)
Recruiting
- Diffuse Large B Cell Lymphoma
- ICP-022
-
Haerbin, Heilongjiang, China
- +5 more
Jul 28, 2021
CNS Lymphoma Trial in Zhengzhou (ICP-022, Pemetrexed)
Recruiting
- Central Nervous System Lymphoma
- ICP-022
- Pemetrexed
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jan 28, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in China (ICP-022, Chlorambucil, Rituximab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- ICP-022
- +2 more
-
Bengbu, Anhui, China
- +55 more
Mar 25, 2022
Systemic Lupus Erythematosus, Rheumatoid Arthritis Trial in Adelaide (ICP-022, Placebos)
Completed
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
- ICP-022
- Placebos
-
Adelaide, South Australia, AustraliaCMAX Clinical Research
Jul 30, 2019